Trial Profile
A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Ketoconazole
- Indications Adenocarcinoma; Endometrial cancer; Glioma; Liver cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Solid tumours; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 29 Jul 2014 New trial record